Oncotarget

Research Papers:

Nestin suppression attenuates invasive potential of endometrial cancer cells by downregulating TGF-β signaling pathway

Amber A. Bokhari, Tabari M. Baker, Batsukh Dorjbal, Sana Waheed, Christopher M. Zahn, Chad A. Hamilton, G. Larry Maxwell and Viqar Syed _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:69733-69748. https://doi.org/10.18632/oncotarget.11947

Metrics: PDF 1108 views  |   HTML 1331 views  |   ?  


Abstract

Amber A. Bokhari1, Tabari M. Baker1 , Batsukh Dorjbal1, Sana Waheed1, Christopher M. Zahn2, Chad A. Hamilton1,3,4, G. Larry Maxwell3,4,5, Viqar Syed1,4,6

1Uniformed Services University, Department of Obstetrics and Gynecology, Bethesda, MD 20814, USA

2American College of Obstetricians and Gynecologists, Washington, DC 20024, USA

3Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA 22003, USA

4John P. Murtha Cancer Center at Water Reed National Military Medical Center, Bethesda, MD 20889, USA

5Inova Fairfax Hospital, Department of Obstetrics and Gynecology, Falls Church, VA 22042, USA

6Uniformed Services University, Department of Molecular and Cell Biology, Bethesda, MD 20814, USA

Correspondence to:

Viqar Syed, email: viqar.syed@usuhs.edu

Keywords: cell proliferation, progesterone, angiogenesis, matrix metalloproteinases, epithelial-mesenchymal-transition

Received: April 25, 2016     Accepted: September 02, 2016     Published: September 10, 2016

ABSTRACT

Nestin, an intermediate filament protein and a stem cell marker is expressed in several tumors. Until recently, little was known about the expression levels and the role of Nestin in endometrial cancer. Compared to the immortalized endometrial epithelial cell line EM-E6/E7-TERT, endometrial cancer cell lines express high to moderate levels of Nestin. Furthermore, endometrial tumors and tumor cell lines have a cancer stem-like cell subpopulation expressing CD133. Among the cancer lines, AN3CA and KLE cells exhibited both a significantly higher number of CD133+ cells and expressed Nestin at higher levels than Ishikawa cells. Knockdown of Nestin in AN3CA and KLE increased cells in G0/G1 phase of the cell cycle, whereas overexpression in Ishikawa decreased cells in G0/G1 phase and increased cells in S-phase. Nestin knockdown cells showed increased p21, p27, and PNCA levels and decreased expression of cyclin-D1 and D3. In contrast, Nestin overexpression revealed an inverse expression pattern of cell cycle regulatory proteins. Nestin knockdown inhibited cancer cell growth and invasive potential by downregulating TGF-β signaling components, MMP-2, MMP-9, vimentin, SNAIL, SLUG, Twist, N-cadherin, and upregulating the epithelial cell marker E-cadherin whereas the opposite was observed with Nestin overexpressing Ishikawa cells. Nestin knockdown also inhibited, while overexpression promoted invadopodia formation and pFAK expression. Knockdown of Nestin significantly reduced tumor volume in vivo. Finally, progesterone inhibited Nestin expression in endometrial cancer cells. These results suggest that Nestin can be a therapeutic target for cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11947